Plus   Neg

Billionaire Robert Smith To Pay $139 Mln To Settle U.S. Tax Investigation

The U.S. Department of Justice announced that Robert Smith, the Chairman and Chief Executive Officer of a San Francisco based private equity company, entered into a non-prosecution agreement on international tax fraud scheme and agreed to pay more than $139 million in taxes and penalties.

In the agreement, Smith admitted his involvement in the illegal scheme and agreed to cooperate with ongoing investigations and to pay back taxes and penalties in full. He also agreed to abandon his protective claims for a refund totaling approximately $182 million that were filed with the IRS in charitable contribution deductions.

The agreement is related to billionaire Smith's involvement from 2000 through 2015 in an illegal scheme to conceal income and evade millions in taxes by using an offshore trust structure and offshore bank accounts.

As per the agreement, Smith formed the Excelsior Trust in Belize, and a shell company, Flash Holdings, in Nevis in 2000. Smith used third-parties to conceal his beneficial ownership and control of the Excelsior Trust and Flash Holdings, but controlled both offshore structures and made all substantive decisions.

Smith used the Excelsior Trust to conceal his ultimate ownership and control over Flash Holdings. He further used Flash Holdings to hide his interest in private equity investments.

Smith admitted that he formed these foreign entities in order to use them to avoid the payment of U.S. taxes.

U.S. Attorney David Anderson for the Northern District of California said, "It is never too late to do the right thing.... Smith committed serious crimes, but he also agreed to cooperate. Smith's agreement to cooperate has put him on a path away from indictment."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration granted emergency use authorization (EUA) for the first and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19. The test confirms recent or prior COVID-19 infection. Developed by Adaptive Biotechnologies, T-Detect COVID Test is a next generation sequencing based (NGS) test. AstraZeneca's one batch of Covid vaccine has been suspended by Austrian health authorities following reports of a death and an illness after receiving vaccination, reports said. The issues were reported in the district clinic of Zwettl in Lower Austria province. The Federal Office for Safety in Health Care in the country said the remaining stocks of the affected AstraZeneca/Oxford Covid-19 vaccine DuPont (DD) announced Monday that it has agreed to acquire Laird Performance Materials from with private equity firm Advent International for $2.3 billion. The company will use existing cash balances for the acquisition. The transaction is expected to close in the third quarter of 2021, subject to regulatory...
Follow RTT